Generic Atralin Availability
ATRALIN (tretinoin - gel;topical)
Manufacturer: DOW PHARM
Approval date: July 26, 2007
Strength(s): 0.05% [RLD]
Has a generic version of Atralin been approved?
An Authorized Generic version of Atralin has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.
List of authorized generic versions:
- Tretinoin TOPICAL GEL .05 g/100g
NDC Code: 620320413
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atralin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Moisturizing vehicle for topical application of vitamin A acid
Issued: September 23, 1997
Inventor(s): Milstein; Elliott A. & Milstein; Nathan
Assignee(s): Dow Pharmaceutical Sciences
A formulation containing tretinoin, a gelling agent, proteinaceous material, and water is provided for the uniform topical application of tretinoin. The water-based formulation is oil- and fat-free, alcohol-free, and rich in proteinaceous material. The formulation is stable over time and is comedogenic and less irritating and drying to the skin.Patent expiration dates:
- September 23, 2014✓
- September 23, 2014
- Atralin Consumer Information (Drugs.com)
- Atralin Consumer Information (Cerner Multum)
- Atralin Topical Advanced Consumer Information (Micromedex®)
- Tretinoin cream Consumer Information (Wolters Kluwer)
- Tretinoin emollient cream Consumer Information (Wolters Kluwer)
- Tretinoin gel Consumer Information (Wolters Kluwer)
- Tretinoin liquid Consumer Information (Wolters Kluwer)
- Tretinoin Emollient Topical Consumer Information (Cerner Multum)
- Tretinoin topical Consumer Information (Cerner Multum)
- Rejuva-A Topical Advanced Consumer Information (Micromedex®)
- Retin-A Micro Topical Advanced Consumer Information (Micromedex®)
- Vitamin A Acid Topical Advanced Consumer Information (Micromedex®)
- Tretinoin Topical Advanced Consumer Information (Micromedex®)
- Tretinoin topical AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|